We dedicate on developing innovative therapies targeting solid tumor drug resistance and metastasis
Priming Tumor Microenvironment
Tumor microenvironment plays a vital role in tumor growth, angiogenesis, metastasis, immune tolerance formation, and the adaptive drug resistance. Tumor with high stroma represent the most challenging tumor types and are associated with poor treatment response and prognosis.
Killing cancer cells via enhanced immunogenic cell death
We are developing novel therapies that can induce stronger immunogenic cell death (ICD) compared to classic chemotherapy or targeted therapy.
During this process, cancer cells will release DAMPs to the tumor microenvironment because of their broken cell membrane caused by the treatment. DAMPs will further boost the maturation of APCs, having the tumor specific antigen presented to and recognized by naive T cells. The naïve T cells will differentiate into cell toxic T cells and remain the memory for the tumor specific antigen, producing sustained anti-tumor effects through the activation of immune system.
|Immunogenic Cell Death||Apoptosis|
- Plasma membrane rupture
- Release of danger signal molecules
- Activation of immune system
- Plasma membrane integrity
- No release of danger signal molecules
- Non-immunogenic clearance of dead cells
lmmunogenic Cell Death (ICD)
“The means by which a cell dies actually matters!”
Adapted from： Kroemer, G., et al. (2013).
Adapted from：Green, D. R., et al. (2009).
Consolidating Treatment via Immuno-Oncology
Anti-tumor effects through enhanced ICD is further amplified and consolidated via immuno-oncology , like bringing immune checkpoint blockers (ICBs) into the battle fields, inhibiting the adaptive response by tumor cells, etc.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
Tel: +86 25-58251030
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing